Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,823 across all filing types
Latest filing 2019-09-13 Foreign Filer Report
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
6-K
Foreign Filer Report
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab A/S regarding the topline results of a Phase III clinical trial (CANDOR study). It details the study's primary endpoint, efficacy data, and safety profile, and mentions future regulatory submissions. It does not contain full financial statements, nor is it a report publication announcement; it is a direct announcement of clinical trial results, which falls under the 'Regulatory Filings' category as a general corporate announcement.
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab A/S regarding the topline results of a Phase III clinical trial (CANDOR study). It details the study's primary endpoint, efficacy data, and safety profile, and mentions future regulatory submissions. It does not contain full financial statements, nor is it a report publication announcement; it is a direct announcement of clinical trial results, which falls under the 'Regulatory Filings' category as a general corporate announcement.
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab A/S regarding the topline results of a Phase III clinical trial (CANDOR study). It details the study's primary endpoint, efficacy data, and safety profile, and mentions future regulatory submissions. It does not contain full financial statements, nor is it a report publication announcement; it is a direct announcement of clinical trial results, which falls under the 'Regulatory Filings' category as a general corporate announcement.
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is a 'Company Announcement' from Genmab A/S regarding the topline results of a Phase III clinical trial (CANDOR study). It details the study's primary endpoint, efficacy data, and safety profile, and mentions future regulatory submissions. It does not contain full financial statements, nor is it a report publication announcement; it is a direct announcement of clinical trial results, which falls under the 'Regulatory Filings' category as a general corporate announcement.
2019-09-13 English
Genmab Announces Positive Topline Results in Phase III Study of Daratumumab in Combination with Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma
Regulatory Filings Classification · 95% confidence The document is titled 'Company Announcement' and details the topline results from the Phase III CANDOR study for the drug daratumumab. It includes key efficacy data (PFS improvement), safety information, and states that the data 'will be submitted to a future medical meeting and Amgen will discuss the data with health authorities in preparation for regulatory submissions.' This format—a press release announcing clinical trial results and future regulatory plans—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a detailed announcement of clinical trial success rather than a routine financial report (like 10-K or IR) or a simple notification of report publication (RPA), and it focuses on material business/clinical progress, it aligns best with an Earnings Release (ER) which often includes significant operational or clinical milestones alongside financial updates, or potentially a Regulatory Filing (RNS) if it were less structured. Given the structure and content (announcing key results), ER is the most appropriate fit among the specific options, as it serves as a major operational update. However, upon reviewing the definitions, this is primarily a clinical trial result announcement, not a standard quarterly financial earnings release (ER). It is a press release announcing a major clinical milestone and future regulatory steps. This type of announcement, which is material but doesn't fit 10-K, IR, or ER (which usually focuses on financial metrics), often falls under general Regulatory Filings (RNS) or sometimes Investor Presentation (IP) if it were a slide deck. Since it is a formal press release announcing trial data and future regulatory plans, and it is not a standard financial report, RNS (Regulatory Filings - general regulatory announcements) is the most suitable fallback category for a significant, non-standard operational update press release.
2019-09-13 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.